Log in

NASDAQ:VCNXVaccinex Stock Price, Forecast & News

+0.14 (+3.78 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $3.84
50-Day Range
MA: $3.81
52-Week Range
Now: $3.84
Volume38,239 shs
Average Volume43,786 shs
Market Capitalization$63.95 million
P/E RatioN/A
Dividend YieldN/A
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.03 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:VCNX



Sales & Book Value

Annual Sales$520,000.00
Book Value($0.10) per share


Net Income$-31,860,000.00
Net Margins-4,740.03%


Market Cap$63.95 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive VCNX News and Ratings via Email

Sign-up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.

Vaccinex (NASDAQ:VCNX) Frequently Asked Questions

How has Vaccinex's stock been impacted by COVID-19 (Coronavirus)?

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX stock has decreased by 7.9% and is now trading at $3.8409. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Vaccinex?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

When is Vaccinex's next earnings date?

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

How were Vaccinex's earnings last quarter?

Vaccinex Inc (NASDAQ:VCNX) posted its earnings results on Thursday, May, 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.75) by $0.30. Vaccinex had a negative net margin of 4,740.03% and a negative return on equity of 2,277.96%. View Vaccinex's earnings history.

What price target have analysts set for VCNX?

1 analysts have issued 12-month target prices for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they anticipate Vaccinex's stock price to reach $22.00 in the next year. This suggests a possible upside of 472.8% from the stock's current price. View analysts' price targets for Vaccinex.

Has Vaccinex been receiving favorable news coverage?

News stories about VCNX stock have been trending negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vaccinex earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news aboutVaccinex.

Are investors shorting Vaccinex?

Vaccinex saw a increase in short interest in May. As of May 15th, there was short interest totaling 190,000 shares, an increase of 13.2% from the April 30th total of 167,900 shares. Based on an average trading volume of 38,000 shares, the days-to-cover ratio is presently 5.0 days. Approximately 6.4% of the shares of the stock are short sold. View Vaccinex's Current Options Chain.

Who are some of Vaccinex's key competitors?

What other stocks do shareholders of Vaccinex own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

Who are Vaccinex's key executives?

Vaccinex's management team includes the following people:
  • Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 73)
  • Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
  • Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
  • Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
  • Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)

When did Vaccinex IPO?

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG served as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

What is Vaccinex's stock symbol?

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Who are Vaccinex's major shareholders?

Vaccinex's stock is owned by many different retail and institutional investors. Top institutional investors include MSD Partners L.P. (7.10%). Company insiders that own Vaccinex stock include Albert Friedberg, Catalyst Group Managem General, Maurice Zauderer and Scott E Royer. View institutional ownership trends for Vaccinex.

Which institutional investors are selling Vaccinex stock?

VCNX stock was sold by a variety of institutional investors in the last quarter, including MSD Partners L.P.. View insider buying and selling activity for Vaccinex.

How do I buy shares of Vaccinex?

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaccinex's stock price today?

One share of VCNX stock can currently be purchased for approximately $3.84.

How big of a company is Vaccinex?

Vaccinex has a market capitalization of $63.95 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

What is Vaccinex's official website?

The official website for Vaccinex is www.vaccinex.com.

How can I contact Vaccinex?

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.